Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 February 2021 | Story Xolisa Mnukwa

The University of the Free State (UFS) invites you to the 2021 Virtual Graduation, where students who completed their qualifications in June/July of 2020 will receive their qualifications during the ceremonies taking place from 22 to 24 February 2021.

Bachelor degrees (435), higher certificates (86), advanced certificates (230), postgraduate certificates (4), national professional diplomas (203), advanced diplomas (13), postgraduate diplomas (158), bachelors honours degrees (22), master’s (201), and doctoral qualifications (70) will be awarded to students across the UFS Bloemfontein and Qwaqwa Campuses. 

Graduates in the faculties of Economic and Management Sciences, Education, Health Sciences, the Humanities, Law, Natural and Agricultural Sciences, and Theology and Religion will be honoured during the upcoming ceremonies for their academic excellence.

Graduation is the highlight on the university calendar, and even though this prestigious occasion will not be taking place traditionally, the UFS would still like to acknowledge and commemorate our graduates’ prestigious accomplishments. 

The COVID-19 pandemic has caused immense disruption in many aspects of our lives. Higher education institutions throughout the world were not exempt from the effects of the deadly virus. This has subsequently impacted the presentation of graduation ceremonies throughout the sector.
The UFS looks forward to virtually celebrating the milestones of all graduates at the virtual graduation ceremonies, and thus implores all graduates to join us in doing so. 

See information further below for details on how to join in on the celebrations.

The university hopes to celebrate many more graduations in future, but for now, the health and safety of our community is our primary concern.
              
  #UFSGraduation2021  #UFSVirtualGraduation 

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept